Ua loaʻa iā AstraZeneca kahi hoʻonui pālua no kāna kōpili oncology i ka Pōʻalua, ma hope o ka ʻae ʻana o nā regulators US a me ʻEulopa i nā hoʻouna kānāwai no kāna mau lāʻau lapaʻau, ʻo ka hana mua i ka lanakila ʻana i kēia mau lāʻau lapaʻau.
ʻO ka Anglo-Swedish lāʻau lapaʻau, a me MedImmune, kona honua noiʻi a me ka hoʻomohala lima, hoʻolaha i ka US Food and Drug Administration (FDA) i ʻae i ka palapala laikini no ka moxetumomab pasudotox, kahi lāʻau lapaʻau hou no ka mālama ʻana i nā poʻe maʻi makua me ka lauoho lauoho. leukemia (HCL) i loaʻa i ʻelua mau lālani lapaʻau ma mua.
Ua hāʻawi ka FDA i ke kūlana o ka lāʻau "priority review", i hāʻawi ʻia i nā lāʻau lapaʻau, inā ʻae ʻia, e hāʻawi i kahi hoʻomaikaʻi nui i ka mālama ʻana, ka maʻi ʻana, a i ʻole ka pale ʻana i nā kūlana koʻikoʻi. Manaʻo ʻia kahi hoʻoholo i ka hapaha ʻekolu o kēia makahiki.
Ma kahi kaʻawale, ua ʻae ka European Medicines Agency i kahi hoʻouna hoʻoponopono no Lynparza, kahi lāʻau i loaʻa iā AstraZeneca i kēia manawa ma kahi hui 50:50 me Merck, ka hui lāʻau lapaʻau US, e mālama i ka maʻi maʻi umauma e laha ana ma nā wahi ʻē aʻe o ke kino no nā maʻi me kahi kikoʻī. hoʻololi genetic.
Inā ʻae ʻia, e lilo ka lāʻau lapaʻau i mea hoʻopale PARP mua no ka mālama ʻana i ka maʻi maʻi umauma ma ʻEulopa. ʻO PARP kahi protein i loaʻa i loko o nā pūnaewele kanaka e kōkua ana i kēlā mau cell e hoʻoponopono iā lākou iho i ka wā e pōʻino ai. Ma ke kāpae ʻana i kēia kaʻina hana hoʻoponopono i loko o nā pūnaewele maʻi maʻi, kōkua ka PARP inhibitors i ka cell e make.
Ua lilo ʻo Lynparza i Ianuali i mea hoʻopaneʻe PARP mua i ʻae ʻia ma nā wahi āpau o ka honua no ka maʻi kanesa o ka umauma, i ka wā i lanakila ai ʻo ia mai nā mea hoʻoponopono US.
I ka hoʻāʻo hou loa, ua hoʻolōʻihi ʻia ʻo Lynparza i ke ola me ka ʻole o ka holomua i ka hoʻohālikelike ʻia me ka chemotherapy a hoʻemi i ka hopena o ka piʻi ʻana o ka maʻi a i ʻole ka make ma 42 pākēneka.
Ma 2017 ka hapalima o nā kūʻai huahana a Astra mai ka oncology a ke manaʻo nei ka ʻoihana e piʻi kēia hapa. Ua pani ʻia nā ʻāpana i ka hui i ka 0.6 pākēneka ma ka £ 49.26.
Ma kahi hoʻomohala ʻokoʻa, ua ʻōlelo ʻo Compugen, kahi hui lāʻau lapaʻau Israeli, ua komo i loko o kahi kuʻikahi laikini kūʻokoʻa me MedImmune e hiki ai i ka hoʻomohala ʻana i nā huahana antibody e mālama i ka maʻi kanesa.
He kuleana ko MedImmune e hana i nā huahana he nui ma lalo o ka laikini "a ʻo ia wale nō ke kuleana no ka noiʻi, hoʻomohala a me nā hana kalepa ma lalo o ka ʻaelike", wahi a Compugen.
E loaʻa i ka hui ʻIseraʻela he $ 10m ma mua o ka uku a hiki iā ia ke loaʻa a hiki i $ 200m i ka hoʻomohala ʻana, ka hoʻoponopono ʻana a me nā mea kūʻai aku no ka huahana mua, a me nā royalties ma ke kūʻai aku ʻana i nā huahana e hiki mai ana.
Ua ʻōlelo ʻo Anat Cohen-Dayag, ka luna nui o Compugen, ʻo ka ʻaelike "e ʻae iā mākou e monetise i nā holomua ʻepekema kikoʻī i kā mākou papahana, ʻoiai mākou e hoʻomau nei i kā mākou mau papahana alakaʻi i nā hoʻokolohua lapaʻau".
Ka manawa hoʻouna: Apr-23-2018